Floatz logo

10 assets in Medullary Thyroid Gland Carcinoma

Therapeutic assets addressing Medullary Thyroid Gland Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cabozantinib
Medullary Thyroid Gland Carcinoma
National Cancer Institute (NCI)P2B (60)
Selpercatinib
Medullary Thyroid Gland Carcinoma
Eli Lilly and CompanyP2B (60)
Tarlatamab
Medullary Thyroid Gland Carcinoma
University of ArizonaP2B (60)
ty-1091
Medullary Thyroid Gland Carcinoma
TYK Medicines, IncP1/2CCC (48)
Fludeoxyglucose
Medullary Thyroid Gland Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Nivolumab
Medullary Thyroid Gland Carcinoma
National Cancer Institute (NCI)P1CC (43)
Copper Cu 64 Anti-Cea Monoclonal Antibody M5A
Medullary Thyroid Gland Carcinoma
City of Hope Medical CenterN/AD (30)
Fluorine (18F) Psma 1007
Medullary Thyroid Gland Carcinoma
University Medical Center GroningenN/AD (30)
Mrna-0523-L001
Medullary Thyroid Gland Carcinoma
Shanghai Jiao Tong University School of MedicineN/AD (30)
Acc-1898
Medullary Thyroid Gland Carcinoma
AccSalus Biosciences, Inc.P1NR ()